Artemis Investment Management LLP Grows Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Artemis Investment Management LLP lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 45.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 78,337 shares of the medical equipment provider's stock after buying an additional 24,548 shares during the quarter. Artemis Investment Management LLP's holdings in Intuitive Surgical were worth $38,798,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Castleark Management LLC lifted its stake in shares of Intuitive Surgical by 3.4% in the 4th quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after purchasing an additional 2,990 shares during the period. Ewing Morris & Co. Investment Partners Ltd. acquired a new position in shares of Intuitive Surgical in the fourth quarter worth about $454,000. Whalerock Point Partners LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter worth about $209,000. Tounjian Advisory Partners LLC purchased a new stake in shares of Intuitive Surgical during the 1st quarter worth about $5,152,000. Finally, Brighton Jones LLC grew its position in shares of Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after acquiring an additional 731 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director now owns 6,371 shares in the company, valued at approximately $3,312,920. This trade represents a 27.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 216 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president now directly owns 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,998 shares of company stock worth $2,611,577 in the last ninety days. 0.70% of the stock is owned by insiders.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $534.19 on Friday. The business's 50 day moving average price is $531.06 and its 200 day moving average price is $536.83. The company has a market cap of $191.46 billion, a price-to-earnings ratio of 78.33, a PEG ratio of 5.53 and a beta of 1.67. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period last year, the company earned $1.50 EPS. On average, analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ISRG has been the topic of a number of recent analyst reports. Erste Group Bank upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Thursday, June 5th. Truist Financial reduced their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Citigroup reissued a "buy" rating and issued a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft cut shares of Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price objective for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. Finally, Evercore ISI dropped their target price on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $588.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.